Jonas Bolander – PharmaTimes
admin Elekta has appointed Jonas Bolander as Acting President and CEO Elekta has announcement the appointment of Jonas Bolander…
Medicine
Orca Bio’s T-cell therapy shows promise in haematological malignancies
The company is preparing to submit the results to the FDA this year Orca Bio has shared promising…
UKHSA announces new effort to tackle hepatitis C
The agency has launched a whole genome sequencing service to monitor the virus The UK Health Security Agency…
Track record – PharmaTimes
Top 5 platforms for measurement-based care in 2025 Measurement-based care (MBC) enhances clinical and therapeutic outcomes through client-reported…
Anocca announces authorisation pancreatic cancer trial
VIDAR-1 trial marks company’s clinical-stage debut Anocca has achieved regulatory approval for its first clinical trial, VIDAR-1, a…
Pfizer’s Talzenna therapy accepted for use within NHS Scotland
Scottish Medicines Consortium approves new option for mCRPC patients Pfizer Ltd has announced that the Scottish Medicines Consortium…
Grifols clinical trial shows positive results for post-polio patients
Immunoglobulin therapy improves mobility in phase 2/3 study Grifols has announced positive results from its phase 2/3 clinical…
Rxulti approved in the European Union for adolescent schizophrenia
EC extends brexpiprazole indication to include adolescents Otsuka Pharmaceutical Europe and Lundbeck have announced that the European Commission…
Orphelia Pharma explores other pathways for paediatric cancer treatment
Company seeks new direction after negative CHMP opinion on KIZFIZO Orphelia Pharma is exploring alternative regulatory pathways for…
Minoryx doses first patient with leriglitazone in Rett syndrome study
Phase 2a TREE study assesses safety and efficacy of leriglitazone Minoryx Therapeutics has dosed the first patient in…
New weight-loss pill shows promising results
Oxford Medical Products targets overweight individuals Oxford Medical Products has announced positive three-month clinical trial results for Sirona,…
Dementia drug neflamapimod shows positive phase 2b trial results
CervoMed’s therapy demonstrates significant improvement in patients CervoMed has announced positive results from the extension phase 2b RewinD-LB…
Agomab announces positive phase 2a interim results for AGMB-129
FSCD therapy meets all endpoints in interim analysis Agomab Therapeutics NV (Agomab) has announced positive interim results from…
Rotherham NHS Foundation Trust enhances patient engagement
Innovative digital transformation leads to significant improvements To reduce waiting lists and enhance patient communication, Rotherham NHS Foundation…
NHS patients receive UK-donated plasma medicines for first time in 30 years
Octapharma supports NHS in building resilient supply chain Octapharma has announced that, for the first time in almost…
Leqembi enters second consultation period following NICE draft guidance update
NICE convenes third committee meeting for additional appraisal consideration Eisai Europe Ltd. and Biogen Idec Ltd. announced that…
SECuRE trial pre-chemo participants experience PSA level drops
Cohort expansion phase commences with promising results The Safety Review Committee (SRC) has confirmed the end of the…
Centauri therapeutics selects first ABX-01 clinical candidate
Lead candidate for lung infections moves to human trials Centauri Therapeutics Limited has announced the selection of its…
Bas Vorsteveld – PharmaTimes
Kenvue appoints Bas Vorsteveld as Managing Director for Northern Europe Kenvue has appointed Bas Vorsteveld as Area Managing…
Blood cancer patients face treatment access disparity
New research highlights NHS approval gap compared to other cancers Research from the Blood Cancer Alliance reveals a…
Professor Dr Uli Brödl – PharmaTimes
Grünenthal has appointed Professor Dr Uli Brödl as CSO Grünenthal has announced that Professor Dr Uli Brödl will…
Chain reaction – PharmaTimes
Pharmaceutical manufacturers in the UK have been navigating complex supply chains for the longest time, balancing the dual…
Pharma unphased
The critical step of navigating post-approval phase
Brainomix partners with Medtronic to enhance stroke care
New collaboration aims to integrate AI solutions for treatment Brainomix, a leader in stroke AI imaging software, has…
Datapharm collaborates with VIDAL to improve medicines information access in France
New partnership to integrate SRD search technology Datapharm, a UK-based provider of medicines information, has announced its expansion…
Mukhtar Ahmed – PharmaTimes
BC Platforms has appointed Mukhtar Ahmed as CEO BC Platforms has announced that it has appointed Mukhtar Ahmed…
Mitazalimab shows promising survival rates in cancer study
Updated data from phase 2 study reveals survival benefit Alligator Bioscience has announced updated results from its phase…
Microbiotica unveils new data on MB097 at AACR IO meeting
Data presented in Los Angeles showcases therapy’s potential Microbiotica, a clinical-stage biopharma company, has presented new data on…
Dubai garden blooms with Boehringer Ingelheim’s lung disease campaign
Awareness of interstitial lung disease raised at Miracle Garden Boehringer Ingelheim, a leading biopharmaceutical company, has teamed up…
Rishi Sunak joins Prostate Cancer Research as an ambassador
Former UK PM advocates for national screening programme Rishi Sunak has joined Prostate Cancer Research as an ambassador…
ICR researchers develop blood test to uncover how childhood tumours adapt
It is hoped that the approach will lead to more targeted treatments for childhood cancers Researchers from the…
Stephan Fritschi – PharmaTimes
Carbogen Amcis has appointed Stephan Fritschi as CEO Carbogen Amcis has appointed Stephan Fritschi, who is currently serving…
FDA approves Deciphera’s Romvimza for rare tumour type
Tenosynovial giant cell tumours can cause pain, stiffness, swelling and movement limitations The US Food and Drug Administration…
Brent Shafer – PharmaTimes
Baxter has appointed Brent Shafer as Chair and Interim CEO Baxter International has appointed Brent Shafer, who has…
UK study highlights importance of GP data in understanding atrial fibrillation
The common heart condition affects approximately 1.5 million people in the UK A new UK study has highlighted…
Heather Knight – PharmaTimes
Baxter has appointed Heather Knight as Executive Vice President and COO Baxter International has appointed Heather Knight, who…
NHS England launches first-ever breast cancer screening campaign
New data has shown that around a third of women do not attend screenings after being invited NHS…
Bath researchers awarded Wellcome grant for psychotic disorder study
New funding to investigate cognitive decline and brain ageing The University of Bath has received a £3.5 million…
Cambridge scientists develop ‘super test’ for prostate cancer
New test aims to revolutionise prostate cancer screening Scientists in Cambridge have developed a new ‘super test’ for…
Illuccix therapy gets approval in the UK
Imaging agent to improve prostate cancer detection Telix Pharmaceuticals has announced that the UK’s Medicines and Healthcare Products…
Andembry treatment approved across Europe
Significant progress for hereditary angioedema condition Global biotechnology leader CSL has announced that the European Commission (EC) has…
Bimekizumab shows long-term efficacy in hidradenitis suppurativa
UCB’s BIMZELX reveals promising two-year data at EHSF 2025 UCB has announced impressive two-year data for BIMZELX (bimekizumab)…
Amlenetug receives FDA Fast Track Designation
Potential treatment for multiple system atrophy shows promise Lundbeck’s investigational drug, amlenetug, has been granted Fast Track Designation…
Lynparza approved in Scotland for BRCA-mutated breast cancer patients
Treatment expands options for HER2-negative metastatic breast cancer AstraZeneca announced that its drug Lynparza (olaparib) has been approved…
Libtayo available in Scotland for cervical cancer patients
New immunotherapy offers hope for recurrent cervical cancer Regeneron UK Limited has announced that the Scottish Medicines Consortium…
Hemgenix shows efficacy among haemophilia B patients
CSL Behring’s study reveals significant long-term benefits New data from CSL Behring’s HOPE-B study demonstrates that Hemgenix (etranacogene…
Capgemini unveils AI breakthrough to boost bioeconomy
New methodology may boost innovation in protein engineering Capgemini has introduced a pioneering generative AI-driven methodology for protein…
FDA grants Orphan Drug Designation to Ariceum cancer therapy
Designation follows promising preclinical data and FDA clearance Ariceum Therapeutics, a private biotech company based in Berlin, has…
Qureight and Avalyn launch strategic partnership in pulmonary fibrosis
Partnership aims to leverage cutting-edge technology in clinical trials Qureight Ltd and Avalyn Pharma Inc have announced a…
Novartis secures MHRA authorisation for ribociclib
Breast cancer therapy offers hope for patients at risk of recurrence Novartis UK announced the Medicines and Healthcare…
Rippon Ubhi – PharmaTimes
Sanofi’s Rippon Ubhi appointed new Chair of European Medicines Group Sanofi has announced that Rippon Ubhi has been…
Algiax announces results from phase 2a trial for neuropathic pain treatment
Study shows AP-325 offers lasting pain relief without central side effects Algiax Pharmaceuticals, a company committed to developing…
Grifols collaborates with startup FcR Therapeutics to develop autoimmune therapies
Partnership aims to create recombinant nanobodies to treat immune disorders Grifols, a global healthcare company and leading manufacturer…
CHMP recommends SC Rybrevant for EGFR-mutated NSCLC patients
Positive opinion issued for marketing authorisation extension The Committee for Medicinal Products for Human Use (CHMP) has recommended…
Aplagon secures EUR 7 million for APAC phase 2a trials
Funding led by new investors FSG and EIC Fund Helsinki-based Aplagon has raised EUR 7 million to advance…
Research resolutions – PharmaTimes
Diversity remains high on the agenda for those designing and delivering clinical trials with the aim of bringing…
Network of trust – PharmaTimes
How the emc supports the accessibility of medicines information Distributing reliable information about medicines is challenging for the…
Janine Schuurman – PharmaTimes
Commit Biologics has appointed Janine Schuurman to its board Commit Biologics has announced the appointment of Janine Schuurman…
Paula Sutherland – PharmaTimes
Alliance Healthcare has appointed Paula Sutherland as Sales Director Alliance Healthcare UK has announced that Paula Sutherland has…
FDA approves new Alzheimer’s treatment regimen
Patients and care partners may find once every four weeks maintenance dosing easier The US Food and Drug…
Cartesian Therapeutics announces FDA agreement for new trial
Phase 3 trial of Descartes-08 in myasthenia gravis to start in 1H25 Cartesian Therapeutics has secured an agreement…
Alligator Bioscience reports survival benefit of mitazalimab with mFOLFIRINOX
Comparison shows improved survival rates for pancreatic cancer treatment Alligator Bioscience has announced positive outcomes from indirect treatment…
Vedanta Biosciences reveals Phase 2 VE303 results
Study highlights VE303’s potential in reducing recurrent CDI Vedanta Biosciences has published additional results from its Phase 2…
Tris Pharma announces positive results from ALLEVIATE-1 trial of cebranopadol
Phase 3 trial shows promising pain relief for acute pain patients Tris Pharma, Inc. has announced positive results…
Zydus announces USFDA Orphan Drug Designation for Usnoflast in ALS treatment
Orphan drug designation offers development incentives and potential market exclusivity Zydus has announced that the USFDA has granted…
AstraZeneca receives positive recommendations for lung cancer treatments
NICE endorses Imfinzi and Tagrisso for enhanced lung cancer care AstraZeneca has received two positive recommendations from the…
Innovative Health Initiative launches a trial aimed at ending Crohn’s Disease
Europe’s first biomarker trial seeks to prevent Crohn’s Disease onset In a landmark effort, the INTERCEPT project has…
EC approves lazertinib in combination with amivantamab for NSCLC patients
Combination therapy shows superior survival benefit over standard treatment The European Commission (EC) has approved the marketing authorisation…
AlzeCure’s NeuroRestore ACD856 to be presented at AD/PD 2025
Preclinical data highlights potential in treating Alzheimer’s disease AlzeCure Pharma AB announced that its abstract on NeuroRestore ACD856…
Datapharm expands into US market through partnership with phactMI
Collaboration aims to enhance accessibility of medicines information Datapharm has announced its expansion into the United States through…
UK sees 70% increase in phase I advanced therapy clinical trials in 2024
Cell and Gene Therapy Catapult reveals significant growth in UK trials The UK experienced a notable increase in…
Gilead and LEO Pharma partner to develop oral STAT6 program
Companies aim to provide new treatments for inflammatory conditions Gilead Sciences and LEO Pharma have announced a strategic…
Actinogen boosts trial with Cambridge Cognition’s digital suite
Partnership aims to advance Alzheimer’s research with innovative tools Cambridge Cognition Holdings plc has expanded its partnership with…
Biofidelity and CellCarta partner to deploy Aspyre Lung in global clinical trials
New partnership to advance precision medicine in lung cancer diagnosis Biofidelity and CellCarta have announced a strategic partnership…
Oxford Drug Design achieves in vivo validation for novel cancer treatment
Promising results from mouse study lead to expanded trials Oxford Drug Design, the Oxford-based AI drug discovery company,…
Owlstone Medical announces $27 million USD first close in Series E financing round
Funds to accelerate commercialisation and clinical trials of diagnostic tests Owlstone Medical has announced a first close of…
Grifols pioneers high-tech analysis of plasma bank to detect Parkinson’s disease
Initiative aims to identify plasma-based biomarkers for early detection Grifols has received a grant from The Michael J.…
Pheno Therapeutics granted trial authorisation for MS candidate
First-in-human trial of PTD802 to commence following UK MHRA approval Pheno Therapeutics Limited has received clinical trial authorisation…
Gilead and LEO Pharma partner to develop oral STAT6 program
Companies aim to provide new treatments for inflammatory conditions Gilead Sciences and LEO Pharma have announced a strategic…
AI set to revolutionise pharmaceutical R&D says GlobalData
Survey finds AI to enhance productivity and cut costs in the next 12 months AI is poised to…
NICE recommends olaparib for BRCA-mutated breast cancer treatment
Groundbreaking approval provides new hope for patients in England and Wales The National Institute for Health and Care…
New therapy hope for prostate cancer patients
CR-discovered NXP800 shows promise in clinical trials Prostate cancer resistant to hormone therapy could soon have a new…
Angelini Ventures co-leads Series A financing in Neumirna Therapeutics
Investment to support RNA therapeutics for epilepsy and neurological disorders Angelini Ventures has co-led a €20 million Series…
Cambridge Cognition highlights positive Cantab results
New FDA-approved schizophrenia treatment shows promise in clinical trials Cambridge Cognition has praised Bristol Myers Squibb for the…
Merck unveils new cyber-physical trust platform at CES 2025
M-Trust set to improve product safety and counterfeiting solutions Merck has launched the beta version of M-Trust, a…
Novartis gene therapy set to enhance SMA treatment
OAV101 IT expands potential for type II SMA patients Novartis has announced that its intrathecal (IT) formulation of…
Amgen’s lung cancer treatment gets conditional approval
IMDYLLTRA offers new hope for patients with extensive-stage small cell lung cancer The UK’s Medicines and Healthcare products…
New prostate cancer test cuts biopsies by 50% in US
EpiSwitch PSE shows promise in reducing unnecessary procedures Kearney Urology Center has reported a 50% reduction in biopsies…
FDA approves Sequana Medical’s Alfapump for ascites treatment
FDA gives green light to innovative device for liver conditions Sequana Medical NV has announced the US FDA…
NHS Confederation welcomes social care commission announcement
Government announces independent commission on social care The government has announced the creation of an independent commission on…
UK regulator warns against buying weight-loss medicines without prescription
MHRA urges caution over illegal medicines from beauty salons and social media The Medicines and Healthcare products Regulatory…
EC approves Rybrevant with Lazcluze for advanced lung cancer
New chemotherapy-free treatment shows promise for EGFR-mutated NSCLC Janssen-Cilag International NV, a Johnson & Johnson company, announced that…
Beckley Psytech announces positive results for ELE-101 in depression trial
Phase 2a study shows promising antidepressant effects Beckley Psytech has announced positive topline results from its phase 2a…
German cancer centre treats first patient with Elekta Evo
New CT-guided radiotherapy system offers personalised cancer treatment Berlin’s Diagnostisch Therapeutisches Zentrum (DTZ) has become the first in…
MindMed begins phase 3 study of MM120 for anxiety disorder
First patient dosed in landmark trial for GAD treatment MindMed has announced the dosing of the first patient…
CSL receives positive opinion for garadacimab in hereditary angioedema
New treatment could revolutionise care for HAE patients Global biotechnology leader CSL has announced that the European Medicines…
Patients pleased? – PharmaTimes
Debra is late getting up for work again. In her heart of hearts, she’s not really enjoying her…
Leriglitazone meets primary endpoint in pivotal cALD trial
Promising trial results support marketing authorisation application Minoryx Therapeutics and Neuraxpharm Group have announced that leriglitazone has met…
Bayer begins inhibitor study treating advanced KRAS-mutated tumours
Trial explores potential of therapy in treating multiple cancer types Bayer has begun a phase 1 clinical trial…
Leriglitazone meets endpoint in trial for cerebral adrenoleukodystrophy
Promising results set stage for European marketing authorization Minoryx Therapeutics and Neuraxpharm Group have announced that leriglitazone met…
iOnctura achieves new clinical milestones in uveal melanoma therapy
Successful phase 1 study highlights potential of roginolisib iOnctura has announced promising results from the phase 1 DIONE-01…
CatalYm shows potential of visugromab for treating cachexia
New findings presented at international SCWD conference CatalYm has announced promising new data on its lead drug candidate,…
Cellenkos presents promising phase 1b data for CK0804 in myelofibrosis
New cell therapy shows potential in treating advanced blood disorder Cellenkos has unveiled new phase 1b data for…
Poolbeg Pharma presents positive results for POLB 001
promising pre-clinical data on preventing cytokine release syndrome Poolbeg Pharma has unveiled encouraging pre-clinical study data for POLB…
Imfinzi receives NICE recommendation for lung cancer treatment
Trial results lead to new treatment option for lung cancer AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has…
NICE endorses Neuraxpharm’s ublituximab for treating MS
New antibody therapy shows promise in managing condition Neuraxpharm Group has announced that the National Institute for Health…
Teva’s Ajovy shows positive results in preventing pediatric migraines
Phase 3 trial indicates significant efficacy and safety for children and adolescents Teva Pharmaceutical Industries has presented positive…
Everest therapy shows promise in nephropathy trial
Data highlights effectiveness of EVER001 in treating pMN Everest Medicines has announced promising results from the Phase 1b/2a…
Antag Therapeutics secures €80 million in weight loss therapy financing
Versant Ventures leads investment round to advance drug Antag Therapeutics has announced the closing of an €80 million…
Orbit Discovery and Evergreen Theragnostics expand research collaboration
Partnership aims to develop new radiopharmaceuticals for cancer treatment Orbit Discovery, based in Oxford, UK, and Evergreen Theragnostics,…
KIMMTRAK recommended for funding by NICE for uveal melanoma patients
Immunocore has announced that Kimmtrak (tebentafusp) has been recommended for funding in England by the National Institute for…
Pharma giants vie for oral GLP-1R approval
Race to create first oral drug for obesity intensifies The competition to gain approval for the first oral…
OGT launches enhanced genetic profiling panel for CLL
new SureSeq CLL + CNV V3 panel improves understanding of CLL OGT has announced the launch of its…
Mikkel Wandahl Pedersen – PharmaTimes
Commit Biologics has appointed Mikkel Wandahl Pedersen as CSO Commit Biologics has announced the appointment of Mikkel Wandahl…
UK grants promising innovative medicine status to CIDP drug
Therapy for autoimmune disorder shows potential Argenx’s investigational therapy, subcutaneous efgartigimod alfa, has been granted Promising Innovative Medicine…
New injection offers hope for asthma and COPD attacks
Injection significantly reduces need for further treatment A new treatment for asthma and COPD attacks could revolutionise patient…
Rab Prinjha – PharmaTimes
Curve Therapeutics has appointed Rab Prinjha as Chief R&D Officer Curve Therapeutics has appointed Rab Prinjha as Chief…
Code makers – PharmaTimes
2024 ABPI Code update has launched – what’s next for pharma and QR codes? The long-anticipated update to…
Mind the gap
How industry and the NHS can work together to bridge the diagnostic gap in COPD
To be precise – PharmaTimes
How oncology therapies can stand out in a diverse, uncertain landscape The oncology field is rapidly evolving, particularly…
Dr Lara Boyd – PharmaTimes
Tessellate BIO has appointed Dr Lara Boyd as CBO Tessellate BIO has appointed Dr Lara Boyd as Chief…
4 ways AI is shaping the future of Life Sciences
There’s no denying it; pharma is in its innovation era. The life sciences industry is already undergoing a…
Dr Daniel Mahony – PharmaTimes
Mahony will continue as the UK government’s Life Sciences Investment Envoy The Department for Science, Innovation and Technology…
Cytomos raises $5m to scale up cell analysis technology production
The biotech will use the funding to drive sales of its first commercial product Cytomos has announced that…
Anthony Harnden – PharmaTimes
The MHRA has appointed Anthony Harnden as Chair The Medicine and Healthcare products Regulatory Agency (MHRA) has appointed…
Ardena’s expanded nanomedicine facility granted full GMP approval
The Netherlands facility is designed to handle a wide range of nanomedicines, including lipid-based nanoparticles Ardena has announced…
Siva Anandaciva – PharmaTimes
The King’s Fund has appointed Siva Anandaciva as Director of Policy, Events and Partnerships The King’s Fund has…
New PAGB research highlights importance of self-care for easy-to-treat conditions
The census found that 56% of people visit their GP for a UTI and 27% for thrush New…
Dr Rima Makarem – PharmaTimes
Somerset NHS Foundation Trust has appointed Dr Rima Makarem as Chair Somerset NHS Foundation Trust has appointed Dr…
Teva and Immunai partner to improve clinical decision making
The companies will focus on mechanisms of action, dose selection and biomarker analyses Teva Pharmaceuticals and artificial intelligence…
AC immune announces positive trial results for early Parkinson’s treatment
Therapy shows high efficacy in initial trial phase AC Immune SA has reported encouraging interim results from its…
Osivax begins phase 2a booster trial for influenza vaccine
First participant vaccinated in study of ovx836 booster dose Osivax, a biopharmaceutical company developing vaccines for broad-spectrum protection…
Vivolta and Neurochase to produce brain therapy catheters
New long-term partnership to address neurological disorder treatments Vivolta, a specialist in medical electrospinning solutions, has entered a…
Microbiotica begins human trials for ulcerative colitis treatment
First patient dosed in phase 1b trial of MB310 therapy Microbiotica, a clinical-stage biopharma company, has announced the…
Infinitopes to showcase cancer vaccine breakthroughs at SITC
Insight into double-blind, phase i/ii clinical trial for oesophageal cancer Infinitopes, an integrated cancer biotech firm, will present…
Lupin to develop near-zero global warming inhalers
Eco-friendly inhalers aim to reduce environmental impact Lupin Healthcare UK Ltd has announced plans to reformulate its pMDI…
Scottish medicines consortium approves CAR T-cell therapy for blood cancer
First car t-cell therapy accepted for second-line treatment in Scotland The Scottish Medicines Consortium (SMC) has approved Kite’s…
SMC recommends Yselty for treating uterine fibroids
New treatment option approved for women in Scotland The Scottish Medicines Consortium (SMC) has recommended Yselty (linzagolix) for…
Elsevier backs Pistoia Alliance for AI in drug discovery
New initiatives to tackle AI-related challenges in life sciences Elsevier, a leader in information and analytics, has announced…
New study to assess mpox vaccine in pregnant women and infants
Trial to evaluate safety and efficacy of MVA-BN vaccine A new scientific trial evaluating Bavarian Nordic’s mpox vaccine…
MHRA grants approval for bladder cancer drug erdafitinib
New therapy targets specific genetic alterations, promises extended survival Johnson & Johnson has announced that the UK’s Medicines…
Arcellx to present positive data on multiple myeloma treatments
Phase 1 and 2 studies show promising results for anito-cel therapy Arcellx Inc, a biotechnology firm focused on…
Dr Jane Rhodes – PharmaTimes
AstronauTx has appointed Dr Jane Rhodes as Chief Executive Officer AstronauTx has appointed Dr Jane Rhodes as Chief…
A rare opportunity – PharmaTimes
Importance of continuous collaboration with rare disease communities At Blueprint Medicines, we aim to make a significant difference…
Trial transformers – PharmaTimes
Building strong partnerships with sites for more effective clinical trials When I first entered the clinical research industry…
Anthony Hemmerdinger – PharmaTimes
Walgreens Boots Alliance appoints Anthony Hemmerdinger as MD, UK and Ireland Walgreens Boots Alliance has announced the appointment…
UK dementia clinical trial participation set to boost by ‘tens of thousands’
The new Dementia Trials Accelerator is set to receive £20m of government funding The Dementia Trials Accelerator, led…
NICE recommends remote monitoring technology for heart failure patients
Heart failure accounted for approximately 90,000 hospital admissions in England in 2019 to 2020 The National Institute for…
WHO report highlights resurgence of tuberculosis
Approximately 8.2 million people were diagnosed with the infectious disease in 2023 The World Health Organization’s (WHO) newly…
Ian Keith – PharmaTimes
Innovative Trials has appointed Ian Keith as Finance and Business Services Director Innovative Trials has appointed Ian Keith,…
NICE recommendation for new Alexion PNH treatment
danicopan shown to improve haemoglobin levels and reduce anaemia Alexion, AstraZeneca Rare Disease, announced that the National Institute…
Laura Vergani – PharmaTimes
Chiesi Group has appointed Laura Vergani as SVP of Global Communications Chiesi Group has announced that Laura Vergani…
Calluna Pharma completes successful phase 1 trial of new fibrotic disease drug
CAL101 shows promising results and is set to enter phase 2 development Calluna Pharma AS has announced the…
Darzalex subcutaneous regimen approved by European Commission
New treatment option for patients with newly diagnosed multiple myeloma The European Commission has approved the subcutaneous (SC)…
Valneva Scotland announces year-long support for local cancer charity Team Jak
The company’s workforce will volunteer and fundraise for Team Jak throughout the year Valneva Scotland has partnered with…
Learna and University of Wolverhampton launch flexible healthcare courses
The five new programmes are designed to fit alongside full-time work and clinical practice Learna and the University…
NICE recommends Santen’s Roclanda to treat glaucoma and ocular hypertension
Primary open-angle glaucoma affects around 2% of adults aged 40 years and older in the UK The National…
Vivan renews five-year lease at UK biotech hub White City Place
The London hub is home to life sciences companies including Novartis, Engitix and invoX Pharma Vivan Therapeutics has…
New £4.5m initiative launched to address UK medicines manufacturing skills shortage
The two-year programme will use virtual reality technology to teach essential skills A £4.5m initiative has been launched…
Richard Hopkins – PharmaTimes
NK:IO has appointed Richard Hopkins as Chief Executive Officer NK:IO has appointed Richard Hopkins, an experienced biologics developer,…
HBC Immunology shares promising results for prostate cancer co-therapy
There are around 55,100 new prostate cancer cases in the UK every year HBC Immunology (HBCI) has announced…
Alleo and Ubiquigent unite to accelerate drug discovery
Partnership to harness AI for DUB-focused preclinical programmes
Celltrion unveils promising dose escalation results for subcutaneous infliximab
Study reveals potential new strategy for managing inflammatory bowel disease
Transgene’s cancer vaccine trial shows mixed results
Phase 2 study of TG4001 shows promise in cervical cancer patients Transgene, a biotech company specializing in virus-based…
Lundbeck to acquire Longboard Pharmaceuticals in strategic deal
Acquisition to enhance Lundbeck’s neuroscience pipeline Lundbeck has announced a significant step forward in its Focused Innovator strategy…
Sanofi launches high-dose flu vaccine in the UK
New vaccine aims to protect older adults from severe flu complications Sanofi has announced the launch of its…
Johnson & Johnson myeloma drug recommended for NHS use
Teclistamab offers hope for patients exhausting treatment options Teclistamab (Tecvayli), a drug manufactured by Johnson & Johnson, has…
Heart patient goes home hours after live-streamed valve replacement
Sheffield cardiologists demonstrate cutting-edge TAVI procedure Cardiologists at Sheffield Teaching Hospitals NHS Foundation Trust have performed a cutting-edge…
Purespring Therapeutics secures £80 million in Series B funding
New investment to advance gene therapies for kidney diseases Purespring Therapeutics has raised £80m in an oversubscribed Series…
Astellas and AviadoBio announce exclusive gene therapy deal
AviadoBio to receive up to £1.8 billion in potential payments AviadoBio and Astellas Pharma have entered into an…
Kyowa Kirin announces positive interim data for lymphoma treatment
Real-world studies show effectiveness of mogamulizumab in routine practice Kyowa Kirin International (KKI) has announced positive interim findings…
Scottish patients first in UK to access new lung cancer treatment
Scottish Medicines Consortium recommends pembrolizumab The Scottish Medicines Consortium (SMC) has recommended MSD’s KEYTRUDA (pembrolizumab) as a monotherapy…
FluoGuide submits clinical trial application for head and neck cancer treatment
Biotech company moves forward with phase 2 trial for precision cancer surgery Copenhagen-based biotech company FluoGuide A/S has…
AlzeCure’s ACD856’s effects to be presented at Alzheimer’s conference
Preclinical data on NeuroRestore therapy to be showcased at CTAD in Madrid AlzeCure Pharma AB, a company specializing…
ERLEADA shows 23% survival benefit over enzalutamide in prostate cancer study
Largest real-world study demonstrates significant survival advantage In a landmark study, Johnson & Johnson has announced that ERLEADA…
IRLAB’s new drug shows promise in treating apathy in Parkinson’s patients
Phase 1 trial of IRL757 demonstrates good absorption and safety profile IRLAB Therapeutics AB has announced the successful…
Insilico Medicine reports positive results for idiopathic pulmonary fibrosis therapy
ISM001-055 shows promise in improving lung function among patients Insilico Medicine, a clinical-stage generative AI-driven drug discovery company,…
European Commission approves Yuvanci for pulmonary arterial hypertension treatment
Janssen-Cilag therapy becomes the first single tablet combination therapy for PAH in europe The European Commission has approved…
Great company – PharmaTimes
ICON celebrates 2024 ‘company of the year’ win ICON continues to celebrate its achievement at the 2024 Clinical…
Lots in translation – PharmaTimes
Harnessing vital patient data for precision in clinical trials In clinical research, leveraging patient data has become a…
Dr Alex Dickinson – PharmaTimes
Sphere Fluidics has appointed Dr Alex Dickinson to its Board of Directors Sphere Fluidics has announced the appointment…
Fabio Gratton – PharmaTimes
minds + assembly has appointed Fabio Gratton as an Advisor minds + assembly welcomes Fabio Gratton as an…
Sheffield A&E to implement life-saving HIV and hepatitis testing
New government scheme to offer routine opt-out blood tests Starting next week, Sheffield’s Northern General Hospital A&E Department…
Oxford drug design secures funding to combat cystic fibrosis lung infections
£3m programme to accelerate new antimicrobial treatment Oxford Drug Design has been awarded a share of a £3…
Dr Amy Walker – PharmaTimes
4basebio has announced Dr Amy Walker as Chief Operating Officer 4basebio has announced the appointment of Dr Amy…
AlgoTx completes pivotal phase 2 trial for ground-breaking CIPN treatment
International trial marks leap forward in chemotherapy-induced neuropathy care In a landmark announcement from Paris, AlgoTherapeutix (AlgoTx) has…
Cancer Grand Challenges launches global initiative to take on toughest problems
International think tanks to shape future of cancer research funding Cancer Grand Challenges, a pioneering initiative co-founded by…
Sundip Chahal
Milieu Insight has appointed Sundip Chahal as Chief Executive Officer
Oncologica to advance urine-based prostate cancer screening test
There is currently no national screening programme for the disease in the UK Oncologica has developed a urine-based…
FlyPharma Europe, Vienna – October 2024 conference
The conference will return to Vienna AirportCity on 23 to 24 October 2024 Samedan has announced that on…
NHS Trust to evaluate AI software for prostate cancer diagnosis
It is hoped that the tool will improve the diagnostic pathway and free up radiologists’ time Leeds Teaching…
Jane Osbourn – PharmaTimes
Alchemab has appointed Jane Osbourn as Chief Executive Officer Alchemab Therapeutics has appointed Jane Osbourn, the company’s Co-Founder…
UKRI’s MRC awards £27.4m to University of Dundee research unit
The centre aims to discover new drug targets for diseases such as Parkinson’s and hypertension The UK Research…
Russell Abberley – PharmaTimes
ABPI has appointed Russell Abberley as Acting President The Association of the British Pharmaceutical Industry (ABPI) has appointed…
WHO adds first mpox vaccine to prequalification list
The decision is expected to facilitate timely access to Bavarian Nordic’s Imvanex The World Health Organization (WHO) has…
Nxera and Cancer Research UK to present promising cancer drug trial at ESMO
Innovative immunotherapy drug HTL0039732 shows potential in trials Nxera Pharma and Cancer Research UK are set to present…
World Sepsis Day 2024 highlights need for better sepsis treatments
GlobalData emphasises importance of Improved clinical trials World Sepsis Day, observed annually on 13 September, aims to raise…
Chemical reaction – PharmaTimes
Chemistry is the cornerstone of modern civilisation, playing a crucial role in virtually every aspect of our lives.…
Centessa reports positive phase 1 clinical data for ORX750
Promising results for novel orexin agonist in sleep-deprived volunteers Nxera Pharma, formerly known as Sosei Group, has announced…
HRT linked to reduced psychosis relapse risk in menopausal women
New study highlights potential benefits of menopausal hormone therapy A recent study published in the American Journal of…